Roche Holding AG
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Global GVHD Clinical Trials Review Reveals Key Trends and Strategic Opportunities for 2025
A comprehensive analysis of the global Graft Versus Host Disease clinical trial landscape shows significant activity across G7 and E7 countries, offering strategic insights for pharmaceutical companies.
Over 220 Pipeline Therapies in Development for Non-Hodgkin's Lymphoma, Reports DelveInsight
DelveInsight's 2025 pipeline report reveals more than 200 companies developing 220+ therapies for Non-Hodgkin's Lymphoma, demonstrating robust research activity in this therapeutic area.
B-Cell Lymphoma Pipeline Expands with 300+ Therapies in Development for 2025
DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area.
Expert Insights: Navigating the Complex Landscape of Biosimilars and Biobetters Development
Biosimilars must demonstrate close similarity to reference products in quality, non-clinical, and clinical data, while biobetters are purposely differentiated to deliver improvements over originators.
Roche to Challenge Illumina's Dominance with Novel Sequencing Technology Launch in 2024
Roche Holding AG announces plans to introduce innovative sequencing by expansion technology in 2024, potentially disrupting Illumina's long-standing market leadership in next-generation sequencing.
Breakthrough Therapy Designations Driving Pharmaceutical Market to Reach $287.5 Billion by 2029
The global market for breakthrough therapies is projected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, representing a compound annual growth rate of 13.8%.
Lupus Nephritis Clinical Trial Landscape Shows Active Development
The lupus nephritis clinical trial pipeline is robust, featuring over 30 companies developing more than 35 therapies.
Global Biotechnology Market Projected to Reach USD 3.54 Trillion by 2033, Driven by Therapeutic Innovations
The global biotechnology market is expected to grow from USD 1.68 trillion in 2024 to USD 3.54 trillion by 2033, representing a CAGR of 9.18%, according to Cervicorn Consulting.
Weight Loss Market Booms as Pharma Responds to Obesity Crisis
The weight loss drugs market is projected to grow at an annual rate of 43.73% through 2032, driven by rising obesity rates and increased employer coverage.
LAG-3 Inhibitors Show Promise in Cancer Immunotherapy, Market Expected to Surge
The LAG-3 inhibitors market is poised for substantial growth, projected to exceed USD 3 billion by 2029, driven by increasing adoption in cancer therapy.